Literature DB >> 23486004

Quantification in (68)Ga-DOTA(0)-Phe(1)-Tyr(3)-octreotide positron emission tomography/computed tomography: can we be impartial about partial volume effects?

Juri Ruf1, Jan Schiefer, Siegfried Kropf, Christian Furth, Gerhard Ulrich, Ortrud Kosiek, Timm Denecke, Marianne Pavel, Andreas Pascher, Bertram Wiedenmann, Holger Amthauer.   

Abstract

AIM: In combined positron emission tomography/computed tomography (PET/CT) of neuroendocrine neoplasms using (68)Ga-DOTA(0)-Phe(1)-Tyr(3)-octreotide ((68)Ga-DOTATOC), partial volume effects (PVEs) may occur in smaller lesions. This study determined the lesional cutoff size for the occurrence of PVEs in a clinical setting.
METHODS: Retrospective assessment of 51 PET/CT examinations (16-slice PET/CT device) for malignant PET foci was carried out. In all foci, the maximal standardized uptake value (SUVmax) and maximal lesion diameter on axial CT was documented. Determined SUVmax and lesional sizes were correlated via LOESS regression. In the resulting curve, the cutoff point for SUVmax size dependency was determined visually and mathematically using 2 approximating straight lines.
RESULTS: In 45 patients, 313 of 413 PET foci found were malignant, measurable on CT and had a roughly spherical geometry (SUVmax: 2.5-103.3, mean ± SD 20.5 ± 15.18; CT diameter: 5-103 mm, mean ± SD 21.8 ± 13.1 mm). The cutoff lesional size for the occurrence of PVEs was 20.4 mm by the mathematical approach and 25 mm by visual assessment.
CONCLUSION: In (68)Ga-DOTATOC imaging, the clinical lesional size threshold is far larger than expected from systemic resolution only. Thus, tracer uptake quantification is only acceptable in sufficiently large lesions.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23486004     DOI: 10.1159/000350418

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  3 in total

1.  Gene transcript analysis blood values correlate with ⁶⁸Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status.

Authors:  L Bodei; M Kidd; I M Modlin; V Prasad; S Severi; V Ambrosini; D J Kwekkeboom; E P Krenning; R P Baum; G Paganelli; I Drozdov
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-05-07       Impact factor: 9.236

2.  A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management.

Authors:  Kjell Oberg; Eric Krenning; Anders Sundin; Lisa Bodei; Mark Kidd; Margot Tesselaar; Valentina Ambrosini; Richard P Baum; Matthew Kulke; Marianne Pavel; Jaroslaw Cwikla; Ignat Drozdov; Massimo Falconi; Nicola Fazio; Andrea Frilling; Robert Jensen; Klaus Koopmans; Tiny Korse; Dik Kwekkeboom; Helmut Maecke; Giovanni Paganelli; Ramon Salazar; Stefano Severi; Jonathan Strosberg; Vikas Prasad; Aldo Scarpa; Ashley Grossman; Annemeik Walenkamp; Mauro Cives; Irene Virgolini; Andreas Kjaer; Irvin M Modlin
Journal:  Endocr Connect       Date:  2016-08-31       Impact factor: 3.335

3.  NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging.

Authors:  Anna Malczewska; Magdalena Witkowska; Karolina Makulik; Agnes Bocian; Agata Walter; Joanna Pilch-Kowalczyk; Wojciech Zajęcki; Lisa Bodei; Kjell E Oberg; Beata Kos-Kudła
Journal:  Endocr Connect       Date:  2019-03-01       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.